TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05795543

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtalar Arthrodesis by Screws
Description: Instruments: cannulated screws Steps: supine position , tournique over the thigh, using a extended lateral approach or sinus tarsi approach with joint debridement and preparation. Single-screw fixation was most often placed from posterior to anterior and double screws fixation was placed triangular pattern

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtalar Arthrodesis by Screws
Description: Instruments: cannulated screws Steps: supine position , tournique over the thigh, using a extended lateral approach or sinus tarsi approach with joint debridement and preparation. Single-screw fixation was most often placed from posterior to anterior and double screws fixation was placed triangular pattern
Study: NCT05914662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib, Bendamustine and Rituximab
Description: Zanubrutinib, 160mg orally, twice a day; Bendamustine 70 mg/m2 on days 1 and 2 of each cycle; Rituximab (375 mg/m2 intravenously on day 0 of each cycle. ZBR was administered every 4 weeks for a total of 6 cycles, followed by maintenance therapy with zanubrutinib monotherapy for another 6 months.
Study: NCT05557162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI ECG Amyloid algorithm
Description: Artificial intelligence enabled electrocardiogram screening tool used to identify the predictive model that best differentiates those at greatest risk for an amyloidosis diagnosis
Study: NCT06113419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy will be performed using the standard American 4-port technique, insufflation will be achieved using CO2 to 15mmHg of pressure. Calot's triangle will be dissected until the critical view of safety is reached, being careful to dissect above the R4U line. After reaching the critical view of safety, two proximal and one distal clip will be placed on both the cystic conduct and artery separately, cutting the clips and then dissecting the gallbladder in a cystfundic direction. When the critical view of safety is not reached, the surgeon may perform a fundus-first cholecystectomy, subtotal cholecystectomy, conversion to open procedure, intraoperative cholangiography or cholecystostomy to their own discretion. It will also be the surgeon's criteria to employ or not a drain system in the surgical site. The decision for theses interventions will be taken intraoperatively and will be according to findings during the procedure.
Study: NCT05757310

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspirate
Description: Undergo bone marrow aspirate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO and IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haploidentical Hematopoietic Cell Transplantation
Description: Undergo CD4+ T-cell depleted haploHCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentostatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06238609

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Group
Description: Subjects will receive a functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
Study: NCT06113419

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy will be performed using the standard American 4-port technique, insufflation will be achieved using CO2 to 15mmHg of pressure. Calot's triangle will be dissected until the critical view of safety is reached, being careful to dissect above the R4U line. After reaching the critical view of safety, two proximal and one distal clip will be placed on both the cystic conduct and artery separately, cutting the clips and then dissecting the gallbladder in a cystfundic direction. When the critical view of safety is not reached, the surgeon may perform a fundus-first cholecystectomy, subtotal cholecystectomy, conversion to open procedure, intraoperative cholangiography or cholecystostomy to their own discretion. It will also be the surgeon's criteria to employ or not a drain system in the surgical site. The decision for theses interventions will be taken intraoperatively and will be according to findings during the procedure.
Study: NCT05452577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suanzaoren Decoction and Huanglian Wendan Decoction
Description: Twice daily. Chinese herbal medicine includes: includes: 25 grams of Suanzaoren, 10 grams of chuanxiong, 30 grams of fushen, 10 grams of Polygala tenuifolia, 10 grams of Pinellia ternata, 12 grams of tangerine peel, 15 grams of Zhuru, 30 grams of forged keel, 30 grams of forged oyster,10 grams of aurantii fructus, 6 grams of coptis chinensis, 30 grams of Albizzia bark.Add or subtract Chinese herbal medicine according to the different clinical manifestations of each patient.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estazolam 1Mg Tab
Description: 1mg tablet once daily
Study: NCT04980521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The radon app
Description: Participants will be asked to use the radon app.
Study: NCT05990088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat Cured Conventional Polymethylmethacrylate Complete Removable Dentures based on neutral zone concept
Description: The patients will receive complete removable dentures designed based on neutral zone concept and manufactured by heat cured conventional technique of polymethylmethacrylate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM Milled Methacrylate Complete Removable Dentures based on neutral zone concept.
Description: The patients will receive complete removable dentures designed based on the neutral-zone concept and digitally manufactured using a milling machineز
Study: NCT06238609

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Subjects will receive a non-functional neuromodulation device to wear for 1 hour daily up to four weeks or until hospital discharge, whichever came first.
Study: NCT05113550

Intervention type: OTHER
Intervention: Surgical remove
Description: liver hydatid cyst (LHC) treated by total or partial pericystectomy

Intervention type: OTHER
Intervention: Surgical remove
Description: liver hydatid cyst (LHC) treated by total or partial pericystectomy
Study: NCT04938180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMB-05X
Description: AMB-05X is a fully human antibody antagonist (immunoglobulin G, type 2 \[IgG2\]) specific to the extracellular domain of human CSF1R
Study: NCT04848051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRC screening reminder
Description: Participants randomized to the CRC Reminder arm will receive reminder that they are due/overdue for CRC screening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRC Reminder & Short message
Description: Participants randomized to the CRC Reminder \& short message arm will receive reminder that they are due/overdue for CRC screening and short message to encourage screening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRC Reminder and Navigation Program
Description: Participants randomized to the CRC reminder and navigation program arm will receive reminder that they are due/overdue for CRC screening and short message to participate in the health navigation program that will connect participants to individually tailored resources and assistance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRC Reminder & CRC education
Description: Participants randomized to the CRC reminder and CRC education program arm will receive reminder that they are due/overdue for CRC screening and offered short educational program conducted online
Study: NCT05970523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercises
Description: Core stabilization exercises are known as a very effective exercise method based on the motor learning principle, performed with the individual's own body weight to strengthen the muscles, improve balance, posture, trunk muscle endurance and flexibility.Each exercise was performed for 7-8 seconds with 10 repetitions. Progression in the exercises was achieved by increasing the difficulty level of the exercises according to the participant's condition once every two weeks.
Study: NCT06008795

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone
Description: Each PPF-active nerve block will consist of 20mg (4ml) ropivacaine plus 4mg (1ml) dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone
Description: Each PPF-active nerve block will consist of 20mg (4ml) ropivacaine plus 4mg (1ml) dexamethasone

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placebo Pteryogpalatine Fossa Injection
Description: Each placebo PPF-injection will consist of 5ml normal saline

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pteryogpalatine Fossa Injection
Description: Each placebo PPF-injection will consist of 5ml normal saline
Study: NCT04980521

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Print brochure
Description: Participants will receive print brochures.
Study: NCT04543110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Immune Modulating Radiation
Description: Neoadjuvant Immune-Modulating Radiation prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Carcinoma
Study: NCT05900141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Description: Pelacarsen 80mg s.c. monthly
Study: NCT05744427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: JSKN003 should be administered intravenously on the first day of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: JSKN003 should be administered intravenously on the first day of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: JSKN003 should be administered intravenously on the first day of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: JSKN003 should be administered intravenously on the first day of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: JSKN003 should be administered intravenously on the first day of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: JSKN003 should be administered intravenously on the first day of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: JSKN003 should be administered intravenously on the first day of each 3-week cycle.
Study: NCT05648422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Saccharomyces Boulardii 200 mg every 12 hours for 6 days at week 1, 5 and 9

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Saccharomyces Boulardii 200 mg every 12 hours for 6 days at week 1, 5 and 9

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NSS Nutritional Support System
Description: Nutritional Support System consists in NSS envelope (glutamine, arginine, folic acid, PUFA-n3, vegetal protein, nicotinic acid, cobalamin, thiamine, pyridoxine, magnesium, zinc, selenium, cholecalciferol, resveratrol, ascorbic acid, Spirulina Máxima, glycine, tryptophan, and inuline) every 12 hours for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deworming
Description: nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deworming
Description: nitazoxanide at a dosage of 7.5 mg / kg every 12 hours for 3 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific diet
Description: This diet focuses on meeting caloric needs according to age, weight, height, and stress factor dividing total caloric value in 50% carbohydrates, 30% lipids, and 20% proteins. It consists of smoothies at breakfast and dinner, high consumption of fish, five meals during the day, 70% of meals eaten during the day will consist on vegetables, fruits, roots, cereals, and legumes. Red meat, gluten, lactose, junk food, sugar, salt, fast food free.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional diet (WHO)
Description: This diet focuses on meeting caloric needs according to age, weight, height, and stress factor dividing total caloric value in 50% carbohydrates, 30% lipids, and 20% proteins. It consists of general nutricional recommendations.
Study: NCT06491173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InfraScanner 2500™
Description: The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
Study: NCT05376774

Intervention type: OTHER
Intervention: Admitted to intensive care units
Description: Admitted to intensive care units
Study: NCT05744427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: JSKN003 should be administered intravenously on the first day of each 3-week cycle.
Study: NCT05579353

Intervention type: OTHER
Intervention: nothing
Description: nothing

Intervention type: OTHER
Intervention: nothing
Description: nothing
Study: NCT06578208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: The patient was placed in the lateral decubitus position by the therapist. The foot was placed on the popliteal fossa of the lower leg while the upper knee was flexed. Once the patient was in this position, the therapist performed high velocity and low amplitude thrusts (HVLA; high velocity - low amplitude) on the vertebra with dysfunction (Fagundes Loss et al., 2020).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: The patient was placed in the lateral decubitus position by the therapist. The foot was placed on the popliteal fossa of the lower leg while the upper knee was flexed. Once the patient was in this position, the therapist performed high velocity and low amplitude thrusts (HVLA; high velocity - low amplitude) on the vertebra with dysfunction (Fagundes Loss et al., 2020).
Study: NCT06275204

Intervention type: DRUG
Intervention: Bismuth-based quadruple therapy
Description: Participants who are positive with H. pylori will receive bismuth-based quadruple therapy:~Antibiotic 1 - Amoxicillin 4 x 500 mg or Clarithromycin 2 x 400 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg.

Intervention type: DRUG
Intervention: Levofloxacin-based quadruple therapy
Description: In case there will be a treatment failure after Protocol I is completed, the remaining patients with a positive infection will be referred to a secondary treatment:~Antibiotic 1 - Levofloxacin 1 x 500 mg, Antibiotic 2 - Metronidazole 4 x 400 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg, Colloidal bismuth - Bismuth oxide 4 x 120 mg.
Study: NCT06336902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given IV
Study: NCT06275204

Intervention type: DRUG
Intervention: Standard triple therapy
Description: Participants who are positive for H. pylori will receive a standard triple therapy:~Antibiotic 1 - Amoxicillin 2 x 1000 mg, Antibiotic 2 - Clarithromycin 2 x 500 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg.

Intervention type: DRUG
Intervention: Levofloxacin-based triple
Description: Participants with treatment failure will be recommended second line treatment - levofloxacin-based:~Antibiotic 1 - Levofloxacin 2 x 500 mg, Antibiotic 2 - Amoxicillin 2 x 1000 mg, Proton pump inhibitor - Esomeprazole 2 x 40 mg
Study: NCT05208073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cosmetic therapy
Description: The cosmetic therapy in this study is once a week, 60 minutes each section for a total of 6-week. Cosmetic therapy uses the teaching materials to teach the subjects skincare and makeup operation steps and use the 10-minute limb stretching to relax their minds before the activity, and then lead the research subjects to use cotton pads to apply lotion and lotion. , female subjects used powder, eyebrow pencil, and lipstick (or lip balm) to complete weekly different-themed activities and hairstyling, while men performed weekly different theme activities and hairstyling.
Study: NCT06204549

Intervention type: OTHER
Group type: OTHER
Intervention: Screening and management of cormobidities
Description: During the routine care assessment and as part of the research, patients will :~* Fill in cardiovascular risk assessment score: Life's simple 7~* Provide an additional blood sample (1 dry tube of 7 mL and 1 heparin tube of 7 mL) during their biological testing. These samples will be used for lipoprotein (a) testing and biological collection.~After hospital discharge, patients will be contacted by telephone at 3 and 12 months for re-evaluation and will fill in the Life's simple 7 score. Prior to this contact, patients will have biological tests as prescribed just before hospital discharge (including blood ionogram, creatinine, liver assessment, lipid assessment (LDL, HDL, triglycerides), fasting blood sugar test, A1C test, urinary albumin/creatinine ratio, protein/ urinary creatinine ratio). They will weigh themselves and take blood pressure self-measurements over 3 days.
Study: NCT06336902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06216457

Intervention type: DEVICE
Intervention: AI software for Stroke
Description: AI Software for Non-Contrast Head CT (Computed Tomography) and CT Angiography, utilized for Code Stroke screening, notification and triage.
Study: NCT06336902

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Undergo FMD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Given IV
Study: NCT06568822

Intervention type: OTHER
Intervention: Asessment
Description: Data prepared by researchers regarding the general characteristics of older adults will be examined.

Intervention type: OTHER
Intervention: The Physical Activity Scale for the Elderly (PASE)
Description: PASE will be used to assess the physical activity levels of older adults.

Intervention type: OTHER
Intervention: Turkish Version of the Satisfaction with Life Scale (T-SWLS)
Description: T-SWLS will be used to assess life satisfaction of older adults.

Intervention type: OTHER
Intervention: Modified Morisky Scale (MMS)
Description: MMS will be used to evaluate medication adherence in older adults.
Study: NCT06575257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: 600 mg orally twice daily for 12 weeks before radical prostatectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg
Description: 3.6 mg goserelin hypodermic once per 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg
Description: 3.6 mg goserelin hypodermic once per 4 weeks
Study: NCT05847868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moment Tumour Hip Prothesis
Description: In the case of irreversible bone loss due to bone tumors, large and multi-part fractures, and pseudarthrosis in the proximal region of the femur bone, the defective bone area is removed and implants made of artificial materials are placed in order to replace the integrity of the bone. In addition, implant applications are made to the proximal femur region for the purpose of revision arthroplasty, which is typically replaced by total hip prosthesis depending on the wear condition.~In this way, the bone integrity will be preserved, long-term stabilization will be provided to the patient and existing pain will be eliminated.~Moment Tumor Hip Replacement Systems consist of proximal main body, extension pieces and intramedullary stems. Components are available in a variety of sizes to meet anatomical requirements and surgeon needs.
Study: NCT05801783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant oncolytic herpes simplex virus type 1 (R130)
Description: R130, a modified herpes simplex virus-1 (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Study: NCT04806893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lerodalcibep
Description: 300 mg subcutaneous injection every month (Q4W)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching subcutaneous injection every month (Q4W)
Study: NCT06216457

Intervention type: DEVICE
Intervention: AI software for Stroke
Description: AI Software for Non-Contrast Head CT (Computed Tomography) and CT Angiography, utilized for Code Stroke screening, notification and triage.

Intervention type: DEVICE
Intervention: AI software for Stroke
Description: AI Software for Non-Contrast Head CT (Computed Tomography) and CT Angiography, utilized for Code Stroke screening, notification and triage.
Study: NCT06260722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC.